245 related articles for article (PubMed ID: 37385752)
21. Insights into recent findings and clinical application of YAP and TAZ in cancer.
Franklin JM; Wu Z; Guan KL
Nat Rev Cancer; 2023 Aug; 23(8):512-525. PubMed ID: 37308716
[TBL] [Abstract][Full Text] [Related]
22. New insights into the ambivalent role of YAP/TAZ in human cancers.
Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
[TBL] [Abstract][Full Text] [Related]
23. Combined control of the fibroblast contractile program by YAP and TAZ.
Link PA; Choi KM; Diaz Espinosa AM; Jones DL; Gao AY; Haak AJ; Tschumperlin DJ
Am J Physiol Lung Cell Mol Physiol; 2022 Jan; 322(1):L23-L32. PubMed ID: 34755530
[TBL] [Abstract][Full Text] [Related]
24. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer.
Zhao C; Zeng C; Ye S; Dai X; He Q; Yang B; Zhu H
Acta Pharm Sin B; 2020 Jun; 10(6):947-960. PubMed ID: 32642404
[TBL] [Abstract][Full Text] [Related]
25. The Hippo pathway mediates inhibition of vascular smooth muscle cell proliferation by cAMP.
Kimura TE; Duggirala A; Smith MC; White S; Sala-Newby GB; Newby AC; Bond M
J Mol Cell Cardiol; 2016 Jan; 90():1-10. PubMed ID: 26625714
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
27. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.
Liu CY; Yu T; Huang Y; Cui L; Hong W
J Biol Chem; 2017 Jun; 292(22):9420-9430. PubMed ID: 28408625
[TBL] [Abstract][Full Text] [Related]
28. Yap/Taz inhibit goblet cell fate to maintain lung epithelial homeostasis.
Hicks-Berthet J; Ning B; Federico A; Tilston-Lunel A; Matschulat A; Ai X; Lenburg ME; Beane J; Monti S; Varelas X
Cell Rep; 2021 Jul; 36(2):109347. PubMed ID: 34260916
[TBL] [Abstract][Full Text] [Related]
29. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
[TBL] [Abstract][Full Text] [Related]
30. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
[TBL] [Abstract][Full Text] [Related]
31. Hierarchy of TGFβ/SMAD, Hippo/YAP/TAZ, and Wnt/β-catenin signaling in melanoma phenotype switching.
Lüönd F; Pirkl M; Hisano M; Prestigiacomo V; Kalathur RK; Beerenwinkel N; Christofori G
Life Sci Alliance; 2022 Feb; 5(2):. PubMed ID: 34819356
[TBL] [Abstract][Full Text] [Related]
32. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways.
Moon H; Park H; Chae MJ; Choi HJ; Kim DY; Ro SW
BMC Cancer; 2022 Apr; 22(1):423. PubMed ID: 35439973
[TBL] [Abstract][Full Text] [Related]
33. Hypoxic conditions differentially regulate TAZ and YAP in cancer cells.
Yan L; Cai Q; Xu Y
Arch Biochem Biophys; 2014 Nov; 562():31-6. PubMed ID: 25078107
[TBL] [Abstract][Full Text] [Related]
34. The Hippo pathway effectors YAP and TAZ interact with EGF-like signaling to regulate expansion-related events in bovine cumulus cells in vitro.
Koch J; Portela VM; Dos Santos EC; Missio D; de Andrade LG; da Silva Z; Gasperin BG; Antoniazzi AQ; Gonçalves PBD; Zamberlam G
J Assist Reprod Genet; 2022 Feb; 39(2):481-492. PubMed ID: 35091965
[TBL] [Abstract][Full Text] [Related]
35. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
36. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
37. Wnt signaling promotes androgen-independent prostate cancer cell proliferation through up-regulation of the hippo pathway effector YAP.
Seo WI; Park S; Gwak J; Ju BG; Chung JI; Kang PM; Oh S
Biochem Biophys Res Commun; 2017 May; 486(4):1034-1039. PubMed ID: 28366633
[TBL] [Abstract][Full Text] [Related]
38. YAP/TAZ: Key Players for Rheumatoid Arthritis Severity by Driving Fibroblast Like Synoviocytes Phenotype and Fibro-Inflammatory Response.
Caire R; Audoux E; Courbon G; Michaud E; Petit C; Dalix E; Chafchafi M; Thomas M; Vanden-Bossche A; Navarro L; Linossier MT; Peyroche S; Guignandon A; Vico L; Paul S; Marotte H
Front Immunol; 2021; 12():791907. PubMed ID: 34956224
[TBL] [Abstract][Full Text] [Related]
39. YAP/TAZ at the Roots of Cancer.
Zanconato F; Cordenonsi M; Piccolo S
Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
[TBL] [Abstract][Full Text] [Related]
40. The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness.
Park H; Lee Y; Lee K; Lee H; Yoo JE; Ahn S; Park YN; Kim H
Pathol Oncol Res; 2021; 27():604600. PubMed ID: 34257565
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
